Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection

计划入组 45 人 · 首次发布于 2018 年 7 月 13 日

Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

计划入组 4 人 · 首次发布于 2018 年 11 月 30 日

Ursodeoxycholic Acid in C. Difficile Infection

计划入组 6 人 · 首次发布于 2022 年 9 月 2 日

C. difficile vaccine(Pfizer)

Therapeutic vaccine (Clostridium difficile infection)

Targeted C. difficile(Pylum Biosciences)

C & C Oxygen Company

United States

FIRST MEDICAL INFECTION CONTROL ASSOCIATES, INC.

United States

Buchanan C Michael

United States

Fecal Microbiota Transplantation Shows Promise for Severe C. difficile Infections Despite Regulatory Challenges

Acurx Receives EMA Approval for Pediatric Investigation Plan for Ibezapolstat in C. difficile Infection

Advances in Clostridioides difficile Research: Rebyota's Continued Efficacy and Vancomycin's Impact